Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
View Patent ↗The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11βHSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable.
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein
R 1 is 5-hydroxy-adamantan-2-yl;
R 2 is aryl, heteroaryl, —C 1-4 alkylene-aryl, or —C 1-4 alkylene-heteroaryl, where the aryl and heteroaryl groups are optionally substituted one or more times with substituents selected independently from the group consisting of halogen, C 1-4 alkyl, —O—C 1-4 alkyl, —CF 3 , —CH 2 CF 3 , —CF 2 CF 3 , and —OCF 3 ;
A 1 is
and
R 3 and R 4 are each independently selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, —O—C 1-4 alkyl, —CF 3 , —CH 2 CF 3 , —CF 2 CF 3 , and —OCF 3 .
2. The compound of claim 1 , wherein A 1 is
and R 3 is hydrogen.
3. The compound of claim 2 , wherein R 2 is phenyl optionally substituted one or two times with substituents selected independently from the group consisting of halogen, C 1-4 alkyl, —O—C 1-4 alkyl, —CF 3 , —CH 2 CF 3 , —CF 2 CF 3 , and —OCF 3 .
4. The compound of claim 2 , wherein R 2 is 2-pyridyl, 3-pyridyl, or 4-pyridyl, each of which is optionally substituted one or more times with substituents selected independently from the group consisting of halogen, C 1-4 alkyl, —O—C 1-4 alkyl, —CF 3 , —CH 2 CF 3 , —CF 2 CF 3 , and —OCF 3 .
5. The compound of claim 4 , wherein R 2 is 2-pyridyl, 3-pyridyl, or 4-pyridyl, each of which is substituted one or two times with chloro.
6. The compound of claim 2 , wherein R 2 is phenethyl or benzyl.
7. The compound of claim 2 , wherein R 2 is —CH 2 -(3-pyridyl), —CH 2 CH 2 -(2-pyridyl), —CH 2 CH 2 -(3-pyridyl), or —CH 2 CH 2 -(4-pyridyl).
8. A compound selected from the group consisting of:
2-[(furan-2-ylmethyl)-amino]-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(5-chloro-pyridin-2-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxyadamantan-2-yl]-amide;
2-(pyridin-4-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(pyridin-3-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(pyridin-2-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(2-phenyl-ethylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(2-pyridin-2-yl-ethylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(4-trifluoromethyl-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(4-methoxy-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(4-chloro-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(4-fluoro-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(3,4-dichloro-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-[(pyridin-3-ylmethyl)-amino]-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-benzylamino-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(2-pyridin-3-yl-ethylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(2-pyridin-4-yl-ethylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
2-(5-chloro-pyridin-2-ylamino)-thiazole-5-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide; and
4-methyl-2-phenethylamino-thiazole-5-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide;
or a pharmaceutically acceptable salt thereof.
9. 2-(5-Chloro-pyridin-2-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9 , wherein the compound is 2-(5-chloro-pyridin-2-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxyadamantan-2-yl]-amide.
11. The compound of claim 9 , wherein the compound is a pharmaceutically acceptable salt of 2-(5-chloro-pyridin-2-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxyadamantan-2-yl]-amide.
12. 2-(Pyridin-3-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide or a pharmaceutically acceptable salt thereof.
13. The compound of claim 12 , wherein the compound is 2-(pyridin-3-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
14. The compound of claim 12 , wherein the compound is a pharmaceutically acceptable salt of 2-(pyridin-3-ylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
15. 2-(2-Phenyl-ethylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide or a pharmaceutically acceptable salt thereof.
16. The compound of claim 15 , wherein the compound is 2-(2-phenyl-ethylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
17. The compound of claim 15 , wherein the compound is a pharmaceutically acceptable salt of 2-(2-phenyl-ethylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
18. 2-(4-Trifluoromethyl-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide or a pharmaceutically acceptable salt thereof.
19. The compound of claim 18 , wherein the compound is 2-(4-trifluoromethyl-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
20. The compound of claim 18 , wherein the compound is a pharmaceutically acceptable salt of 2-(4-trifluoromethyl-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
21. 2-(4-Methoxy-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide or a pharmaceutically acceptable salt thereof.
22. The compound of claim 21 , wherein the compound is 2-(4-methoxy-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
23. The compound of claim 21 , wherein the compound is a pharmaceutically acceptable salt of 2-(4-methoxy-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
24. 2-(4-Fluoro-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide or a pharmaceutically acceptable salt thereof.
25. The compound of claim 24 , wherein the compound is 2-(4-fluoro-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
26. The compound of claim 24 , wherein the compound is a pharmaceutically acceptable salt of 2-(4-fluoro-phenylamino)-thiazole-4-carboxylic acid [(E)-5-hydroxy-adamantan-2-yl]-amide.
27. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
28. A pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier.
29. A pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable carrier.
30. A pharmaceutical composition comprising a compound of claim 12 and a pharmaceutically acceptable carrier.
31. A pharmaceutical composition comprising a compound of claim 15 and a pharmaceutically acceptable carrier.
32. A pharmaceutical composition comprising a compound of claim 18 and a pharmaceutically acceptable carrier.
33. A pharmaceutical composition comprising a compound of claim 21 and a pharmaceutically acceptable carrier.
34. A pharmaceutical composition comprising a compound of claim 24 and a pharmaceutically acceptable carrier.
35. A method of treating a disease, disorder, or condition comprising administering to a subject an amount of a compound of claim 1 , where the disease, disorder, or condition is selected from the group consisting of: metabolic syndrome, type 2 diabetes, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), dyslipidemia, obesity, hypertension, arteriosclerosis, atherosclerosis, myopathy, muscle wasting, osteoporosis, adverse effects of treatment or therapy with glucocorticoid receptor agonists, and dysregulation of intraocular pressure including glaucoma.
36. A method of treating metabolic syndrome comprising administering to a subject an amount of a compound of claim 1 .
37. A method of treating type 2 diabetes comprising administering to a subject an amount of a compound of claim 1 .
38. A method of treating the adverse effects of treatment or therapy with a glucocorticoid receptor agonist comprising administering to a subject an amount of a compound of claim 1 .
39. A method of treating a dysregulation of intraocular pressure, including glaucoma, comprising administering to a subject an amount of a compound of claim 1 .
40. A method of reducing intracellular glucocorticoid levels in a human tissue comprising administering to a subject an amount of a compound of claim 1 .
41. A method of reducing intraocular pressure comprising administering to a subject an amount of a compound of claim 1 .